Compare Abbott Laboratories (ABT) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Seagate Technology Holdings PLC — how do they compare? Abbott Laboratories trades at $95.42 (market cap $166.94B), while Seagate Technology Holdings PLC trades at $834.81 (market cap $187.26B). The key difference: Abbott Laboratories and Seagate Technology Holdings PLC are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | STX | |
|---|---|---|
Market Cap | $166.94B | $187.26B |
Sector | Health | Technology |
52-Week High | $136.62 | $1.09K |
52-Week Low | $82.57 | $142.01 |
Enterprise Value | $193.69B | $190.29B |
Dividend Yield | 2.63% | 0.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
STX trades at $827.64, up 0.91% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamental momentum, with Q1 2026 EPS of $4.10 beating expectations of $3.51, continuing a trend of earnings beats. Revenue for 2025 reached $9.10 billion with a net income margin of 21.6%, while valuation ratios like P/E of 82.38 and P/B of 179.4 reflect high growth expectations. Recent news highlights STX as a top momentum stock amid AI-driven demand, despite sector volatility.
The outlook for STX is positive, driven by robust earnings growth and AI infrastructure demand, with a consensus price target of $955.71 implying 15% upside. Risks include high debt levels, with a debt-to-asset ratio of 73.31% in 2024, and sensitivity to memory market fluctuations, as seen in recent sell-offs. Investor sentiment remains bullish among analysts, with 51% buy ratings, but technical weakness warrants caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
